Eli Lilly & Co. reported positive results for its JAK1/2 inhibitor Olumiant (baricitinib) in combination with topical corticosteroids in the third of five Phase III clinical trials in atopic dermatitis (AD) with data readouts this year. However, a pulmonary embolism experienced by a patient treated with the drug in the ex-US trial raises questions about whether JAK inhibitors are viable treatments for AD given safety concerns.
Lilly's Latest Olumiant Data Raise Question Of JAK Inhibitor Role In Atopic Dermatitis
While the BREEZE-AD7 data show that baricitinib may effectively treat AD in combination with topical corticosteroids, a patient treated with the drug in the ex-US study had a pulmonary embolism.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.